TY - JOUR
T1 - Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma
AU - Cistaro, Angelina
AU - Cassalia, Laura
AU - Ferrara, Cinzia
AU - Quartuccio, Natale
AU - Evangelista, Laura
AU - Bianchi, Maurizio
AU - Fagioli, Franca
AU - Bisi, Gianni
AU - Baldari, Sergio
AU - Zanella, Alessandro
AU - Pillon, Marta
AU - Zucchetta, Pietro
AU - Burei, Marta
AU - Sala, Alessandra
AU - Guerra, Luca
AU - Guglielmo, Priscilla
AU - Burnelli, Roberta
AU - Panareo, Stefano
AU - Scalorbi, Federica
AU - Rambaldi, Ilaria
AU - Piccardo, Arnoldo
AU - Garaventa, Alberto
AU - Familiari, Demetrio
AU - Fornito, Maria Concetta
AU - Lopci, Egesta
AU - Mascarin, Maurizio
AU - Altini, Corinna
AU - Ferrari, Cristina
AU - Perillo, Teresa
AU - Santoro, Nicola
AU - Borsatti, Eugenio
AU - Rubini, Giuseppe
PY - 2018/6
Y1 - 2018/6
N2 - The present study investigated the utility of fluorine-18 (18F) fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL). 18F-FDG PET/CT shows high diagnostic performance in evaluating BMI in pediatric HL. BMB should be ideally reserved for patients with doubtful 18F-FDG PET/CT BMI findings. Introduction: The present study investigated the utility of fluorine-18 (18F) fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL). Patients and Methods: A total of 224 pediatric patients with HL underwent 18F-FDG PET/CT at staging. BMB or follow-up imaging was used as the standard of reference for the evaluation of BMI. Results: 18F-FDG PET/CT was negative for BMI in 193 cases. Of the 193 patients, the findings for 16 were originally reported as doubtful and later interpreted as negative for BMI, with negative findings on follow-up imaging and BMB. At BMB, 1 of the 16 patients (6.25%) had BMI. Of the 193 patients, 192 (99.48%) had negative BMB findings. Thus, the 18F-FDG PET/CT findings were truly negative for 192 patients and falsely negative for 1 patient for BMI. Conclusion: 18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
AB - The present study investigated the utility of fluorine-18 (18F) fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL). 18F-FDG PET/CT shows high diagnostic performance in evaluating BMI in pediatric HL. BMB should be ideally reserved for patients with doubtful 18F-FDG PET/CT BMI findings. Introduction: The present study investigated the utility of fluorine-18 (18F) fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL). Patients and Methods: A total of 224 pediatric patients with HL underwent 18F-FDG PET/CT at staging. BMB or follow-up imaging was used as the standard of reference for the evaluation of BMI. Results: 18F-FDG PET/CT was negative for BMI in 193 cases. Of the 193 patients, the findings for 16 were originally reported as doubtful and later interpreted as negative for BMI, with negative findings on follow-up imaging and BMB. At BMB, 1 of the 16 patients (6.25%) had BMI. Of the 193 patients, 192 (99.48%) had negative BMB findings. Thus, the 18F-FDG PET/CT findings were truly negative for 192 patients and falsely negative for 1 patient for BMI. Conclusion: 18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
KW - BMI
KW - Bone marrow biopsy
KW - Computed tomography
KW - Newly diagnosed pediatric HL
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=85046709721&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.04.002
DO - 10.1016/j.clml.2018.04.002
M3 - Article
AN - SCOPUS:85046709721
SN - 2152-2650
VL - 18
SP - e267-e273
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 6
ER -
